Drug Trial Radar · NCT01288027
Exploratory Muscle Biopsy Assessment Study in Patients With Late-Onset Pompe Disease Treated With Alglucosidase Alfa
Last checked: Nov 20, 2026Latest source record: Dec 19, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
16
Actual
Start
Jun 2011
Primary completion
Dec 2013
Study completion Dec 2013
Sponsor
- Lead sponsor
- Genzyme, a Sanofi CompanySanofi (SNY)
- Sponsor type
- Industry
- First posted
- Feb 2, 2011
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, multicenter study of participants with late-onset Pompe disease naive to treatment with enzyme replacement therapy (ERT). The primary objective of this study is to evaluate glycogen clearance in muscle tissue samples collected pre and post alglucosidase alfa treatment in participants with Late-Onset Pompe disease. The secondary objectives are to characterize the disease burden in participants with late-onset Pompe disease and explore imaging, histologic, and functional assessments in these participants and to explore potential plasma or urine biomarkers relative to late-onset Pompe disease and participant's response to treatment with alglucosidase alfa (Myozyme®/Lumizyme®/GZ419829).
Conditions
- Pompe Disease (Late-Onset)
- Glycogen Storage Disease Type II (GSD II)
- Glycogenesis 2 Acid Maltase Deficiency
Interventions
Alglucosidase AlfaBiological
Alglucosidase alfa intravenous infusion 20 milligram per kilogram (mg/kg) every other week for 24 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Tissue Glycogen Content in Quadriceps Muscle Biopsy Samples at Week 26Time frame: Baseline, Week 26
Locations
15 sites in 4 countries. Site status is shown where the registry gives one.
Site not named
Orange, California
Site not named
Gainesville, Florida
Site not named
Kansas City, Kansas
Site not named
St Louis, Missouri
Site not named
New York, New York
Site not named
Durham, North Carolina
Site not named
Colombus, Ohio
Site not named
Heshey, Pennsylvania
Site not named
Fairfax, Virginia
Site not named
Mainz, Germany
Site not named
München, Germany
Site not named
Münster, Germany
Site not named
Rotterdam, Netherlands
Site not named
Newcastle upon Tyne, United Kingdom
Site not named
Salford, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.